Switzerland · Series D startup
Funding summaryUpdated 26 Oct 2026
$194Mraised across 2 rounds since 2019, from 3 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
OrbiMedLead
Bpifrance
RA Capital Management
Morningside Group
Novo Holdings
Catalio Capital Management
Longitude Capital
Frazier Life Sciences
Jeito CapitalReported by Firms' own news pages and 1 other
Reported by FinSMEs
From Alentis Therapeutics's own website: 1 founder, 8 on the team.
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Missing a round, or an investor who was in one? Tell us.
These 3 firms list Alentis Therapeutics as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.
Alentis Therapeutics's investors include Bpifrance, OrbiMed, BioMedPartners, BB Pureos Bioventures and RA Capital Management, and 11 more on record. OrbiMed led its latest round.
Alentis Therapeutics has raised $194M across 2 rounds since 2019.
Alentis Therapeutics's most recent round was a Series D of $181M in Nov 2024, led by OrbiMed.
Its most recent round, $181M in Nov 2024, is also its largest on record.
Alentis Therapeutics's first round on record, in May 2019, was backed by BioMedPartners, BB Pureos Bioventures and Bpifrance and 2 others.
Alentis Therapeutics's latest named round is a Series D, in Nov 2024.
Alentis Therapeutics is based in Switzerland.
BioMedPartners led the Series A in 2019; OrbiMed led the Series D in 2024.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
Switzerland · 
